Tests trastuzumab deruxtecan with immunotherapy for HER2-expressing endometrial cancer
Tests a HER2-targeted drug with immunotherapy as first treatment in adults with advanced endometrial cancer.
Key facts
- Who runs it
- AstraZeneca
- Where
- Goyang-si, Seoul, and Suwon, South KoreaSee the 3 sitesAlso in 22 other countries, 224 sites
- Trial code
- Registry title
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 600 people, planned
- Started
- 27 Mar 2025
- Expected to end
- 19 Feb 2031
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Trastuzumab deruxtecan
- Rilvegostomig
- Pembrolizumab
- Carboplatin
- Paclitaxel
- Docetaxel
- Record updated
- 16 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or recurrent endometrial cancer that is HER2-positive (IHC 3+ or 2+) and mismatch repair proficient (pMMR), who have not had treatment for it yet.
- Age
- 18 years or older
- Sex
- Women
- Disease stage
- Endometrial carcinoma that is advanced (Stage III or IV) or has come back. Sarcomas are not allowed; carcinosarcomas are allowed. Stage III needs measurable disease.
- Earlier treatment
- No earlier chemotherapy for this cancer, except one round of adjuvant or neoadjuvant chemotherapy with the aim of removing all of the disease, finished at least 6 months before. No earlier antibody-drug conjugates or immune checkpoint inhibitors. Earlier radiation and hormone therapy are allowed.
- Biomarker or test result
- HER2 IHC 3+ or 2+ and pMMR, both confirmed by central testing. A tumor tissue sample is needed for central testing.
Main reasons for not taking part
- History of or current lung inflammation (ILD/pneumonitis) or serious lung disease
- Serious heart problems, such as a heart attack or unstable angina within 6 months, or symptomatic heart failure
- History of organ transplant or allogeneic stem cell transplant
- Active autoimmune or inflammatory disease needing long-term systemic treatment
- Active central nervous system metastases, active tuberculosis, active hepatitis B or C, or HIV that is not well controlled
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- ≥ 18 years of age at the time of screening. Other age restrictions may apply as per local regulations
- Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies are allowed except for sarcomas (carcinosarcomas are allowed)
- Participant must have primary advanced disease (Stage III/IV) or recurrent endometrial cancer and meet at least one of the following criteria:; Primary Stage III (per FIGO 2023) disease with measurable disease at baseline per RECIST 1.1 based on the investigator's assessment; Primary Stage IV (per FIGO 2023) disease regardless of presence of measurable disease at baseline; Recurrent disease regardless of presence of measurable disease at baseline
- Endometrial cancer with HER2 IHC expression of 3+ or 2+ by prospective central testing
- Endometrial cancer that is determined pMMR by prospective central testing
- Provision of an adequate FFPE tumor tissue sample for central HER2, MMR, and PD-L1 IHC testing
- Prior therapy:; No prior chemotherapy for the treatment of EC, except for one prior line of adjuvant/ neoadjuvant chemotherapy with curative intent (chemotherapy or chemoradiation) if completed ≥ 6 months prior to signature of the main ICF. Prior trastuzumab in the adjuvant/neoadjuvant setting is allowed; No prior exposure to antibody-drug conjugates or immune checkpoint inhibitors; Participants may have received prior radiation therapy for the treatment of endometrial cancer. Adequate treatment washout period is required; Participants may have received prior hormonal therapy for the treatment of endometrial cancer. Adequate treatment washout period is required
- ECOG 0-1
- Left ventricular ejection fraction ≥ 50% within 28 days before randomization
- Adequate organ and bone marrow function within 14 days before randomization
- The participant is not considered a candidate for curative therapy in the judgment of the investigator
Who cannot take part
- Active or prior documented autoimmune or inflammatory disorders requiring chronic systemic treatment with the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs
- Lung criteria:; Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, etc.); Any autoimmune, connective tissue or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of screening; Prior pneumonectomy (complete)
- History of myocardial infarction or unstable angina within 6 months before randomization, or symptomatic congestive heart failure (NYHA Class II to IV), clinically significant arrhythmia, uncontrolled hypertension, cardiomyopathy of any etiology or history of myocarditis
- Any severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or would jeopardize compliance with the protocol
- Active or ongoing serious chronic gastrointestinal conditions associated with diarrhea, primary immunodeficiency, or non-infectious skin disease requiring systemic treatment
- History of (non-infectious) ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- History of organ transplant or allogeneic stem cell transplant
- Evidence of any of the following infections:; Active tuberculosis; HIV infection that is not well controlled; Active hepatitis B or C infection
- Spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive brain metastases may be included in the study
Where in South Korea
Also in 22 other countries, 224 sites
- Goyang-siHospital not named in the registryTaking people
- SeoulHospital not named in the registryTaking people
- SuwonHospital not named in the registryTaking people
About the trial
What the trial wants to find out
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
The 3 groups in the trial
- Arm A: T-DXd + RilvegostomigTreatment being tested
T-DXd IV Q3W plus rilvegostomig IV Q3W. Treatment will continue until objective disease progression according to RECIST v1.1 as assessed by the Investigator and confirmed by BICR or until other discontinuation criteria is met, whichever occurs first.
Treatment: Trastuzumab deruxtecan and Rilvegostomig
- Arm B: T-DXd + PembrolizumabTreatment being tested
T-DXd IV Q3W plus pembrolizumab IV Q3W. Treatment will continue until objective disease progression according to RECIST v1.1 as assessed by the Investigator and confirmed by BICR or until other discontinuation criteria is met, whichever occurs first.
Treatment: Trastuzumab deruxtecan and Pembrolizumab
- Arm C: Carboplatin + Paclitaxel + PembrolizumabExisting treatment, for comparison
Carboplatin, paclitaxel and pembrolizumab administered Q3W for 6 cycles, followed by maintenance with pembrolizumab IV Q6W for 14 cycles. Treatment with pembrolizumab will continue for up to 20 total cycles (approximately 24 months, accounting for combination and maintenance phases) or until other discontinuation criteria is met, whichever occurs first. At the discretion of the investigator, participants may continue to receive carboplatin, paclitaxel and pembrolizumab Q3W for up to 10 cycles. Docetaxel can be used as an alternative to paclitaxel for participants who had a hypersensitivity reaction to paclitaxel with a failed rechallenge (or not amenable to rechallenge), according to the investigator's clinical judgment.
Treatment: Pembrolizumab, Carboplatin, Paclitaxel, and Docetaxel
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
- Plain-language title
- Tests trastuzumab deruxtecan with immunotherapy for HER2-expressing endometrial cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 November 2026